Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.

@article{Abraldes2016AdditionOS,
  title={Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.},
  author={Juan G Abraldes and C. V{\'a}zquez – Villanueva and C. Fernandez Aracil and Juan Turnes and Manuel Hern{\'a}ndez-Guerra and Joan Genesc{\`a} and Manuel Jes{\'u}s Manrique Rodr{\'i}guez and J. C. Castellote and Juan Carlos Garc{\'i}a-Pag{\'a}n and Ferran Torres and Jos{\'e} Luis Ibarrola Calleja and Agust{\'i}n Albillos and J Bosch},
  journal={Gastroenterology},
  year={2016},
  volume={150 5},
  pages={
          1160-1170.e3
        }
}
BACKGROUND & AIMS The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis. METHODS We performed a multicenter, double-blind… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

Similar Papers

Loading similar papers…